Fourth-gen CAR T Cells Targeting CD19/CD22 therapy(Essen Biotech)

N/A

Report date: 2024/04/03 20:05:50

Base Information

Drug NameFourth-gen CAR T Cells Targeting CD19/CD22 therapy(Essen Biotech)
Drug Alias NameT-cell Infusion Targeting CD19 and CD2 therapy(Essen Biotech)CD19/CD22-CAR T cells therapy(Essen Biotech)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulatorsCD22 modulators
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsCentral Nervous System LymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEssen Biotech
China Registration ClassN/A

Develop Information

Active CompaniesEssen Biotech
Inactive CompaniesN/A
Active IndicationsCentral Nervous System LymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A